Cargando…

Visualizing spatial distribution of alectinib in murine brain using quantitative mass spectrometry imaging

In the development of anticancer drugs, drug concentration measurements in the target tissue have been thought to be crucial for predicting drug efficacy and safety. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) is commonly used for determination of average drug concentrations; however,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aikawa, Hiroaki, Hayashi, Mitsuhiro, Ryu, Shoraku, Yamashita, Makiko, Ohtsuka, Naoto, Nishidate, Masanobu, Fujiwara, Yasuhiro, Hamada, Akinobu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4812395/ https://www.ncbi.nlm.nih.gov/pubmed/27026287 http://dx.doi.org/10.1038/srep23749

Ejemplares similares

MALDI mass spectrometry imaging of erlotinib administered in combination with bevacizumab in xenograft mice bearing B901L, EGFR-mutated NSCLC cells
por: Nishidate, Masanobu, et al.
Publicado: (2017)

Visualization of the distribution of nanoparticle-formulated AZD2811 in mouse tumor model using matrix-assisted laser desorption ionization mass spectrometry imaging
por: Ryu, Shoraku, et al.
Publicado: (2020)

Evaluation of the heterogeneous tissue distribution of erlotinib in lung cancer using matrix-assisted laser desorption ionization mass spectrometry imaging
por: Tsubata, Yukari, et al.
Publicado: (2017)

A novel method for evaluating antibody-dependent cell-mediated cytotoxicity by flowcytometry using cryopreserved human peripheral blood mononuclear cells
por: Yamashita, Makiko, et al.
Publicado: (2016)

Distribution of erlotinib in rash and normal skin in cancer patients receiving erlotinib visualized by matrix assisted laser desorption/ionization mass spectrometry imaging
por: Nishimura, Meiko, et al.
Publicado: (2018)

MPC-11 IDH1/2 MUTATIONS ARE ASSOCIATED WITH SEIZURE ONSET AND VETRY IMAGING IN PATIENTS WITH DIFFUSE GLIOMA VISUALIZING 2-HYDROXYGLUTARATE BY MASS SPECTRUM
por: Ohno, Makoto, et al.
Publicado: (2019)

A Therapeutic Strategy to Combat HIV-1 Latently Infected Cells With a Combination of Latency-Reversing Agents Containing DAG-Lactone PKC Activators
por: Matsuda, Kouki, et al.
Publicado: (2021)

Durable responses to alectinib in murine models of EML4-ALK lung cancer requires adaptive immunity
por: Kleczko, Emily K., et al.
Publicado: (2023)

Alectinib-induced Immune Hemolytic Anemia in a Patient with Lung Adenocarcinoma
por: Okumoto, Joe, et al.
Publicado: (2020)

Effect of Hepatic Impairment on the Pharmacokinetics of Alectinib
por: Morcos, Peter N., et al.
Publicado: (2018)

Alectinib-Induced Erythema Multiforme and Successful Rechallenge with Alectinib in a Patient with Anaplastic Lymphoma Kinase-Rearranged Lung Cancer
por: Kimura, Tatsuo, et al.
Publicado: (2016)

Metabolites of alectinib in human: their identification and pharmacological activity
por: Sato-Nakai, Mika, et al.
Publicado: (2017)

Progressive renal insufficiency related to ALK inhibitor, alectinib
por: Nagai, Kojiro, et al.
Publicado: (2018)

Development of Alectinib-Suspended SNEDDS for Enhanced Solubility and Dissolution
por: Park, Eun Ji, et al.
Publicado: (2022)

Pharmacokinetic profiles of significant adverse events with crizotinib in Japanese patients with ABCB1 polymorphism
por: Fujiwara, Yutaka, et al.
Publicado: (2016)

Phase II Trial of the Combination of Alectinib with Bevacizumab in Alectinib Refractory ALK-Positive Nonsquamous Non-Small-Cell Lung Cancer (NLCTG1501)
por: Watanabe, Satoshi, et al.
Publicado: (2022)

Large Cell Neuroendocrine Carcinoma Harboring an Anaplastic Lymphoma Kinase (ALK) Rearrangement with Response to Alectinib
por: Hayashi, Nobuyoshi, et al.
Publicado: (2017)

Dramatic response to alectinib in a patient with ALK‐rearranged squamous cell lung cancer
por: Shiihara, Jun, et al.
Publicado: (2021)

Dramatic Response to Alectinib in a Critically Ill Elderly Patient with Lung Adenocarcinoma Due to Trousseau Syndrome and Disseminated Intravascular Coagulation
por: Hamada, Noboru, et al.
Publicado: (2021)

Comparison of Alectinib/Crizotinib Data in First-Line Therapy in Patients with Anaplastic Lymphomakinase-Positive Nonsmall Cell Lung Carcinoma with Poor Prognostic Features for Alectinib
por: Katgı, Nuran, et al.
Publicado: (2023)

ALK-Positive Squamous Cell Carcinoma Dramatically Responded to Alectinib
por: Sagawa, Ray, et al.
Publicado: (2018)

Major pathologic response to alectinib in ALK-rearranged adenocarcinoma of the lung
por: Imanishi, Naoko, et al.
Publicado: (2018)

Patient-reported outcomes in a phase II study of alectinib
por: Ohe, Yuichiro
Publicado: (2018)

Alectinib Induced Regression of Renal and Hepatic Cysts Caused by Crizotinib
por: Di Marino, Pietro, et al.
Publicado: (2020)

Alectinib-associated drug reaction with eosinophilia and systemic symptoms syndrome
por: Farooq, Sahira, et al.
Publicado: (2020)

STRN-ALK, A Novel In-Frame Fusion With Response to Alectinib
por: Nagasaka, Misako, et al.
Publicado: (2020)

Alectinib-Induced Pleural and Pericardial Effusions in ALK-Positive NSCLC
por: Ulhoi, Maiken Parm, et al.
Publicado: (2021)

Alectinib for Miliary Lung Metastasis in ALK-Positive Lung Adenocarcinoma
por: Satoh, Hironori, et al.
Publicado: (2021)

High incidence and reversible bradycardia events following alectinib initiation
por: Yuan, Dongqi, et al.
Publicado: (2022)

Photophysical Exploration of Alectinib and Rilpivirine: Insights from Theory and Experiment
por: Zhang, Chun, et al.
Publicado: (2023)

Case report: Indolent drug-related pneumonitis with alectinib therapy in the treatment of non-small cell lung cancer
por: Chen, Xianmeng, et al.
Publicado: (2022)

Spatial localization of β-unsaturated aldehyde markers in murine diabetic kidney tissue by mass spectrometry imaging
por: Harkin, Carla, et al.
Publicado: (2022)

Characteristics of central nervous system progression in non‐small cell lung cancer treated with crizotinib or alectinib
por: Sakamoto, Hiroaki, et al.
Publicado: (2021)

Successful alectinib treatment after crizotinib‐induced interstitial lung disease
por: Fujiuchi, Satoru, et al.
Publicado: (2016)

Regression of Crizotinib-Associated Complex Cystic Lesions after Switching to Alectinib
por: Taima, Kageaki, et al.
Publicado: (2017)

Successful treatment with crizotinib after alectinib-induced interstitial lung disease
por: Zhu, Ning, et al.
Publicado: (2021)

STRN-ALK Fusion–Positive Case of Breast Cancer With Response to Alectinib
por: Kelly, Andrew D., et al.
Publicado: (2021)

Is Elevation of Alkaline Phosphatase a Predictive Factor of Response to Alectinib in NSCLC?
por: Shalata, Walid, et al.
Publicado: (2021)

Complete response to alectinib in ALK-fusion metastatic salivary ductal carcinoma
por: Adashek, Jacob J., et al.
Publicado: (2023)

The Long Half-Life of Programmed Cell Death Protein 1 Inhibitors May Increase the Frequency of Immune-Related Adverse Events After Subsequent EGFR Tyrosine Kinase Inhibitor Therapy
por: Shinno, Yuki, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_0evll01ho1k338eip6l0jq8df6